The work
How it works
For CEOs and commercial leads at CGT, biologics and platform companies. You have a partner, deal or U.S. launch decision due in the next 90 days.
What we look at
Tap a service to open it.
Partner map
Which CDMO, CRO, or platform fits this molecule and this stage.
Short list. Why these, not those.
Deal design
RFI/RFP, scope, and risk. Follow-the-molecule or split vendors.
A contract that survives tech transfer.
Intro path
West Coast biotech, CGT, and oncology seats.
Open the room that can actually decide.
Commercial story
Sell the science without over-claiming capacity.
What you can run now. Where the proof sits. What is still platform risk.
The first SKU
Commercial Decision Sprint
21 days. One commercial decision—partner, path, or story.
Written down and defended before your dated event.
What you leave with
- A partner short list mapped to molecule and stage
- A build path: one partner vs split
- Risk notes that belong in the contract
- A decision memo you can put in front of a room
The 21 days
Days 1–3
Frame the single decision and the event date.
Days 4–12
Map partners, path, and story. One working session.
Days 13–18
Draft the memo. You react once.
Days 19–21
Final memo, 30-day actions, optional defense.
Fixed diagnostic. Credited if a mandate continues within 60 days.
Technical sprints scoped on the briefing.
The house
TBA Intelligence. Signals → a call you can make.
TBA Advisory. Senior commercial judgment, by engagement.
TBA Growth. Fractional BD when a full desk is too early.
TBA Connect. Company-to-company introductions under the room.
Mission
TBA turns emerging life-science signals into strategic advantage.
The commercial layer between intelligence shops, banks, and conferences — seen before the map is drawn.
Biotech Mafia is a TBA network. Not the legal entity. Not the SKU. →
Have a board date, RFP or site visit on the calendar? That’s the right time to talk.
Five questions. A 20-minute briefing if it fits, a clear no if not.